查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1624445

核医学/放射性医药品的全球市场规模:各用途，手术数，各类型，各地区，范围及预测

Global Nuclear Medicine/Radiopharmaceuticals Market Size By Application, By Procedural Volume, By Type, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

核医/放射性药物市场规模及预测

2020 年核医/放射性药物市场规模价值 65.6 亿美元，预计到 2028 年将达到 135.3 亿美元，2021 年至 2028 年的复合年增长率为 9.47%。

预测期内，神经系统应用对放射性药物的需求将推动核医/放射性药物市场的成长。全球核子医学/放射性药物市场报告对市场进行了全面评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

定义全球核医/放射性药物市场

为了诊断目的而给予患者并透过某些影像方式监测的放射性化合物称为放射性药物。放射性药物用于治疗和诊断目的。放射性药物主要是带有放射性同位素的有机分子。过去 50 年来，由于对化学的投入不断增加以及放射性核素和放射性标记化合物的发展，核子医学得到了长足的发展。

全球核子医学/放射性药物市场概况

全球核医/放射性药物市场的成长是由目标疾病的发生率和盛行率的增加所推动的。基于α铁疗法的标靶癌症治疗的需求不断增加，因此全球核医/放射性药物市场正在快速成长。

然而，一些阻碍因素正在限制全球核医/放射性药物市场的成长。放射性药物的保质期短可能会阻碍全球核医/放射性药物市场的成长。此外，高昂的设备成本也可能阻碍全球核医/放射性药物市场的成长。

目录

第1章 全球核医学/放射性医药品市场简介

  • 市场概要
  • 调查范围
  • 前提条件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的调查手法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源一览

第4章 全球核医学/放射性医药品市场展望

  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 波特的五力分析
  • 价值链分析

第5章 核医学/放射性医药品的全球市场:各用途

  • 概要
  • 诊断用途
    • SPECT用途
  • 其他的SPECT用途
    • PET用途
    • 治疗用途
    • 甲状腺
    • 骨转移
    • 淋巴瘤
    • 内分泌肿瘤
    • 其他的治疗用途

第6章 核医学/放射性医药品的全球市场:手术数

  • 概要
  • 诊断手术
    • SPECT放射性医药品
    • PET放射性医药品
  • 治疗手术
    • β线发送器
    • α射线放出核种
    • 近距离放射治疗的同位素

第7章 全球核医学/放射性医药品市场:各类型

  • 概要
  • 诊断用核医学
    • SPECT放射性医药品
  • PET放射性医药品
    • F-18
    • 铷82
    • 其他的PET同位素
  • 治疗用核医学/放射性医药品
    • β线放出核种
    • α射线放出核种
    • 近距离放射治疗的同位素

第8章 核医学/放射性医药品的全球市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲各地区
    • 德国
    • 英国
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 全球其他地区
    • 南美
    • 中东·非洲

第9章 全球核医学/放射性医药品市场竞争情形

  • 概要
  • 各公司的市场排行榜
  • 主要的开发策略

第10章 企业简介

  • Cardinal Health, Inc.
  • Mallinckrodt PLC
  • GE Healthcare(A Fully-Owned Subsidiary of General Electric Company)
  • Lantheus Medical Imaging, Inc.
  • Bayer AG
  • Bracco Imaging S.P.A
  • Eczacibasi-Monrol Nuclear Products
  • Nordion, Inc.(A Subsidiary of Sterigenics International LLC.)
  • Advanced Accelerator Applications S.A.
  • Iba Molecular

第11章 附录

  • 相关报告
简介目录
Product Code: 24378

Nuclear Medicine/Radiopharmaceuticals Market Size And Forecast

Nuclear Medicine/Radiopharmaceuticals Market size was valued at USD 6.56 Billion in 2020 and is projected to reachUSD 13.53 Billion by 2028, growing at aCAGR of 9.47% from 2021 to 2028.

The demand for radiopharmaceuticals in neurological applications will drive the growth of the Nuclear Medicine/Radiopharmaceuticals Market during the forecast period. The Global Nuclear Medicine/Radiopharmaceuticals Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Nuclear Medicine/Radiopharmaceuticals Market Definition

The radioactive compounds administered to the patient and monitored via a specific imaging device for diagnostic purposes are known as radiopharmaceuticals. This drug can be used for therapeutic or diagnostic purposes. The radiopharmaceuticals are mainly composed of a radioisotope bond to an organic molecule. Over the last 50 years, nuclear medicine has developed significantly owing to increasing investments in the field of chemistry and the development of radionuclides and radiolabeled compounds.

Global Nuclear Medicine/Radiopharmaceuticals Market Overview

The growth of the global Nuclear Medicine/Radiopharmaceuticals Market is being driven by increasing incidences and prevalence of target conditions. The demand for alpha radioimmunotherapy-based targeted cancer treatment is increasing and owing to which the global Nuclear Medicine/Radiopharmaceuticals Market is flourishing at a rapid pace.

However, some restraints are liming the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. The short life span of radiopharmaceuticals may create setbacks for the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. Also, the high equipment prices may hamper the growth of the global Nuclear Medicine/Radiopharmaceuticals Market.

Global Nuclear Medicine/Radiopharmaceuticals Market: Segmentation Analysis

The Global Nuclear Medicine/Radiopharmaceuticals Market is Segmented on the basis of Application, Procedural Volume, Type, and Geography.

Nuclear Medicine/Radiopharmaceuticals Market, By Application

  • 1.1 Diagnostic Applications
    • 1.1.1 SPECT Applications
    • 1.1.1.1 Cardiology
    • 1.1.1.2 Neurology
    • 1.1.1.3 Thyroid
  • 1.2 Other SPECT Applications
    • 1.2.1 PET Applications
    • 1.2.1.1 Oncology
    • 1.2.1.2 Cardiology
    • 1.2.1.3 Neurology
    • 1.2.1.4 Other PET Applications
    • 1.2.2 Therapeutic Applications
    • 1.2.3 Thyroid
    • 1.2.4 Bone Metastasis
    • 1.2.5 Lymphoma
    • 1.2.6 Endocrine Tumors
    • 1.2.7 Other Therapeutic Applications

Based on Application, the market is segmented into Diagnostic Applications and Other SPECT Applications. The diagnostic applications dominated the global Nuclear Medicine/Radiopharmaceuticals Market. The SPECT applications especially contributed majorly to the growth of the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume

  • 2.1 Diagnostic Procedures
    • 2.1.1 SPECT Radiopharmaceuticals
    • 2.1.2 PET Radiopharmaceuticals
  • 2.2 Therapeutic Procedures
    • 2.2.1 Beta Emitters
    • 2.2.2 Alpha Emitters
    • 2.2.3 Brachytherapy Isotopes

Based on Procedural Volume, the market is segmented into Diagnostic Procedures and Therapeutic Procedures. The Diagnostic Procedures are further bifurcated into SPECT Radiopharmaceuticals, PET Radiopharmaceuticals, and Therapeutic Procedures. The Therapeutic Procedures are further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The Diagnostic Procedures dominated the global Nuclear Medicine/Radiopharmaceuticals Market.

Nuclear Medicine/Radiopharmaceuticals Market, By Type

  • 3.1 Diagnostic Nuclear Medicine
    • 3.1.1 SPECT Radiopharmaceuticals
    • 3.1.1.1 Tc-99m
    • 3.1.1.2 Tl-201
    • 3.1.1.3 Ga-67
    • 3.1.1.4 I-123
    • 3.1.1.5 Other SPECT Isotopes
  • 3.3 PET Radiopharmaceuticals
    • 3.2.1 F-18
    • 3.2.2 Rubidium-82
    • 3.2.3 Other PET Isotopes
  • 3.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals
    • 3.3.1 Beta Emitters
    • 3.3.1.1 Iodine-131
    • 3.3.1.2 Y-90
    • 3.3.1.3 Sm-153
    • 3.3.1.4 Re-186
    • 3.3.1.5 Lu-177
    • 3.3.1.6 Other Beta Emitters
    • 3.3.2 Alpha Emitters
    • 3.3.2.1 Ra-223
    • 3.3.3 Brachytherapy Isotopes
    • 3.3.3.1 Iodine-125
    • 3.3.3.2 Iridium-192
    • 3.3.3.3 Palladium-103
    • 3.3.3.4 Cesium-131
    • 3.3.3.5 Other Brachytherapy Isotopes

Based on Type, the market is segmented into Diagnostic Nuclear Medicine, PET Radiopharmaceuticals, and Therapeutic Nuclear Medicine/Radiopharmaceuticals. The Therapeutic Nuclear Medicine/ Radiopharmaceuticals is further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The alpha emitters segment dominated the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on regional analysis, the Global Nuclear Medicine/Radiopharmaceuticals Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America. The dominance of the North American region can be attributed to the development of novel technologies for radioscopic production and an increase in government funding.

Key Players

  • The "Global Nuclear Medicine/Radiopharmaceuticals Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Cardinal Health, Inc., Mallinckrodt PLC, GE Healthcare (A Fully-Owned Subsidiary of General Electric Company), Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.P.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc. (A Subsidiary of Sterigenics International LLC.), Advanced Accelerator Applications S.A., Iba Molecular.
  • These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Key Developments

  • Partnerships, Collaborations and Agreements
  • A manufacturing and distribution deal was signed in 2019 between Eczacba-Monrol and Telix Pharmaceuticals Limited (Australia). Telix has engaged Eczacba-Monrol as a radiopharmaceutical production partner and distributor throughout Turkey, the Middle East, and North Africa, according to the conditions of the agreement.
  • Mergers and Acquisitions
  • In the year 2019, Curium acquired MAP Medical, allowing it to expand its footprint in Europe and gain direct access to the Nordic and Baltic countries.
  • Product Launches and Product Expansions
  • Curium (France) and NRG (Netherlands) inked a Molybdenum-99 manufacturing agreement in 2019.
  • Cobalt-60 was purchased from the Board of Radiation and Isotope Technology (BRIT) in April 2019 for distribution throughout Europe by Nordion, Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 5.1 Overview
  • 5.2 Diagnostic Applications
    • 5.2.1 SPECT Applications
    • 5.2.1.1 Cardiology
    • 5.2.1.2 Neurology
    • 5.2.1.3 Thyroid
  • 5.3 Other SPECT Applications
    • 5.3.1 PET Applications
    • 5.3.1.1 Oncology
    • 5.3.1.2 Cardiology
    • 5.3.1.3 Neurology
    • 5.3.1.4 Other PET Applications
    • 5.3.2 Therapeutic Applications
    • 5.3.3 Thyroid
    • 5.3.4 Bone Metastasis
    • 5.3.5 Lymphoma
    • 5.3.6 Endocrine Tumors
    • 5.3.7 Other Therapeutic Applications

6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

  • 6.1 Overview
  • 6.2 Diagnostic Procedures
    • 6.2.1 SPECT Radiopharmaceuticals
    • 6.2.2 PET Radiopharmaceuticals
  • 6.3 Therapeutic Procedures
    • 6.3.1 Beta Emitters
    • 6.3.2 Alpha Emitters
    • 6.3.3 Brachytherapy Isotopes

7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 7.1 Overview
  • 7.2 Diagnostic Nuclear Medicine
    • 7.2.1 SPECT Radiopharmaceuticals
    • 7.2.1.1 Tc-99m
    • 7.2.1.2 Tl-201
    • 7.2.1.3 Ga-67
    • 7.2.1.4 I-123
    • 7.2.1.5 Other SPECT Isotopes
  • 7.3 PET Radiopharmaceuticals
    • 7.3.1 F-18
    • 7.3.2 Rubidium-82
    • 7.3.3 Other PET Isotopes
  • 7.4 Therapeutic Nuclear Medicine/ Radiopharmaceuticals
    • 7.4.1 Beta Emitters
    • 7.4.1.1 Iodine-131
    • 7.4.1.2 Y-90
    • 7.4.1.3 Sm-153
    • 7.4.1.4 Re-186
    • 7.4.1.5 Lu-177
    • 7.4.1.6 Other Beta Emitters
    • 7.4.2 Alpha Emitters
    • 7.4.2.1 Ra-223
    • 7.4.3 Brachytherapy Isotopes
    • 7.4.3.1 Iodine-125
    • 7.4.3.2 Iridium-192
    • 7.4.3.3 Palladium-103
    • 7.4.3.4 Cesium-131
    • 7.4.3.5 Other Brachytherapy Isotopes

8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 EuropeRegional
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Cardinal Health, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Mallinckrodt PLC
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Lantheus Medical Imaging, Inc.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Bayer AG
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Bracco Imaging S.P.A
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Eczacibasi-Monrol Nuclear Products
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Advanced Accelerator Applications S.A.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Iba Molecular
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Reports